NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Practice this question and more.


Which medication is contraindicated in structural heart disease (HF, MI)?

  1. Flecainide and Propafenone

  2. Quinidine and Disopyramide

  3. Mexiletine and Lidocaine

  4. Sotalol and Dronedarone

The correct answer is: Flecainide and Propafenone

In structural heart disease such as heart failure (HF) or myocardial infarction (MI), medications that can further worsen the condition should be avoided. In this case, both Flecainide and Propafenone are Class I antiarrhythmic drugs that have negative inotropic effects and can exacerbate heart failure and increase the risk of arrhythmias in patients with structural heart disease. Therefore, it is contraindicated to use Flecainide and Propafenone in patients with structural heart disease. The other options: B. Quinidine and Disopyramide: These are also Class I antiarrhythmic drugs and can have similar effects as Flecainide and Propafenone in patients with structural heart disease. C. Mexiletine and Lidocaine: These are Class Ib antiarrhythmic drugs that have less negative inotropic effects compared to Class Ia drugs like Flecainide and Propafenone. They may be considered in certain situations in patients with structural heart disease. D. Sotalol and Dronedarone: While Sotalol is a Class III antiarrhythmic drug that can prolong the QT interval and should be used with caution in patients with structural heart disease, Dronedarone is a Class III antiarrhythmic drug that is generally considered safer in patients with structural heart disease compared to Flecainide and Propafenone, but still should be used with caution.